Natco Pharma on Monday said the Delhi High Court has permitted the company to launch Chlorantraniliprole (CTPR) and its formulations through its non-infringing process.
CTPR technology has been developed into broad spectrum insecticides used in wide range of crops for pest management. The market size of CTPR enabled products in India is estimated to be over ₹2,000 crore. Natco said that the company plans to introduce its products very soon.
The drugmaker, which diversified into agrochemicals a few years back, said it was the first company in the country to register by the Central Insecticides Board and Registration Committee for indigenous manufacture of Chlorantraniliprole (CTPR) technical 93.00%, in early 2021. approval was obtained. w/w min. Under section 9(3).
While the latest release from Natco Pharma did not share additional details about the court case. The company said in July 2021 that the Delhi High Court had allowed an application by US-based FMC Corp challenging the use of the pest control active ingredient CTPR. FMC sued CTPR for possible patent infringement.
In response to the judgment, on the interim injunction application filed by the FMC, Natco said it would review all options. The US firm said at the time that the interim injunction prohibited Natco from manufacturing, using, distributing or selling any products containing CTPR.